• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Gilead opens innovative new laboratory, announces additional $100M investment

Gilead opens innovative new laboratory, announces additional $100M investment

May 28, 2015
CenterWatch Staff

Gilead Alberta, a wholly-owned subsidiary of Gilead Sciences, has opened the first of two new laboratory buildings at its Edmonton, Canada campus, and announced an additional $100 million investment to further expand and upgrade the site as the biopharmaceutical company broadens its pipeline of treatments in areas of unmet medical need.

Gilead Alberta's two new laboratory buildings will allow for close to 170 additional scientists in Edmonton and enable Gilead Alberta to expand to support the development and manufacturing of investigational drugs, supply active pharmaceutical ingredients (API) for clinical research programs and contribute to new product launch supplies in the areas of hepatitis C virus (HCV), HIV/AIDS and oncology. A second laboratory building is under construction and set for completion in the spring of 2016.

The additional $100 million investment at the campus will include the construction of a new process tower for the additional manufacturing of API, a maintenance facility and upgrades to the existing site. The process tower will expand the capabilities of the operations in Edmonton to allow for the handling of more potent compounds.

Edmonton is home to Gilead's largest operation in Canada, with more than 300 employees. In 2014, Gilead invested more than $100 million in R&D in Canada, almost half of that in Alberta.

In Alberta, Gilead initiatives support the province's advanced education system and not-for-profit sector such as the Northern Alberta Institute of Technology's (NAIT) Chemical Technology program, the Industrial Internship Program at the University of Alberta and the Centennial Centre for Interdisciplinary Sciences at the University of Alberta. Gilead staff also support and volunteer with many local programs across Edmonton, including the CapitalCare Foundation and the annual AIDS Walk for Life.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing